Choosing phase II endpoints and designs: evaluating the possibilities.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22407830.
- Also identified by DOI 10.1158/1078-0432.CCR-12-0454 and PMC identifier 4820349.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Selecting the phase II design and endpoint to achieve the best possible chance of success for a confirmatory phase III study in a particular disease and treatment setting is challenging but critical. Simulating from existing clinical trial data sets and from mathematical models can be useful tools for evaluating statistical properties.
Medical subject headings
- Benzenesulfonates
- Clinical Trials, Phase III as Topic
- Kidney Neoplasms
- Pyridines
- Randomized Controlled Trials as Topic
- Research Design